Myocardial infarction in mice treated with thymosin beta4
How the study was set up
Mice with experimentally induced heart attacks received full-length thymosin beta4 or vehicle for seven days or five weeks.
What the researchers measured
Cardiac rupture, ultrasound-measured function, inflammatory cells, cell death, collagen, capillary density, and protein markers were examined.
How to read this evidence
Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.
Results in context
The study reports both early injury and later remodeling outcomes in mice. It cannot establish post-heart-attack treatment in people or equivalence to TB-500.
What this does not establish
An induced mouse infarction and full-length thymosin beta4 do not establish human cardiac treatment or TB-500 efficacy.
This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.
Publication & source
Why this paper is included
The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.
Publication indexing
Journal Article · Research Support, N.I.H., Extramural · Research Support, Non-U.S. Gov't